Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia

Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. He...

Full description

Saved in:
Bibliographic Details
Main Authors: Kengo Ayabe, Tomoyoshi Komiyama, Hiroyuki Takekawa, Honsa Kang, Yasuaki Tsumagari, Miwa Ito, Keiichi Ashikaga, Yoshisato Shibata
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/60/11/1782
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850226749552459776
author Kengo Ayabe
Tomoyoshi Komiyama
Hiroyuki Takekawa
Honsa Kang
Yasuaki Tsumagari
Miwa Ito
Keiichi Ashikaga
Yoshisato Shibata
author_facet Kengo Ayabe
Tomoyoshi Komiyama
Hiroyuki Takekawa
Honsa Kang
Yasuaki Tsumagari
Miwa Ito
Keiichi Ashikaga
Yoshisato Shibata
author_sort Kengo Ayabe
collection DOAJ
description Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. Hence, this study aimed to evaluate the effectiveness of landiolol in patients with atrial fibrillation (AF) and atrial tachycardia (AT), not limited to those with heart failure with a reduced ejection fraction. To this end, we evaluated the efficacy and safety of landiolol in managing tachycardiac AF and tachycardiac atrial flutter/AT in 44 patients with reduced left ventricular function. We found that while landiolol was effective in managing patients with AF and heart failure with a preserved or mid-range ejection fraction, however, it might be more challenging to control heart rate in patients with AT using a similar dosage of landiolol.
format Article
id doaj-art-28bb64c68c2d4968bdbfc0013ef21fac
institution OA Journals
issn 1010-660X
1648-9144
language English
publishDate 2024-10-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-28bb64c68c2d4968bdbfc0013ef21fac2025-08-20T02:04:59ZengMDPI AGMedicina1010-660X1648-91442024-10-016011178210.3390/medicina60111782Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial TachycardiaKengo Ayabe0Tomoyoshi Komiyama1Hiroyuki Takekawa2Honsa Kang3Yasuaki Tsumagari4Miwa Ito5Keiichi Ashikaga6Yoshisato Shibata7Cardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, JapanDepartment of Clinical Pharmacology, Tokai University School of Medicine, Isehara 259-1193, JapanCardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, JapanFukuoka City Hospital Cardiology Department, Fukuoka 812-0046, JapanCardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, JapanCardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, JapanCardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, JapanCardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, JapanLandiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. Hence, this study aimed to evaluate the effectiveness of landiolol in patients with atrial fibrillation (AF) and atrial tachycardia (AT), not limited to those with heart failure with a reduced ejection fraction. To this end, we evaluated the efficacy and safety of landiolol in managing tachycardiac AF and tachycardiac atrial flutter/AT in 44 patients with reduced left ventricular function. We found that while landiolol was effective in managing patients with AF and heart failure with a preserved or mid-range ejection fraction, however, it might be more challenging to control heart rate in patients with AT using a similar dosage of landiolol.https://www.mdpi.com/1648-9144/60/11/1782landiololHFpEFHFmrEFHFrEFβ-blocker
spellingShingle Kengo Ayabe
Tomoyoshi Komiyama
Hiroyuki Takekawa
Honsa Kang
Yasuaki Tsumagari
Miwa Ito
Keiichi Ashikaga
Yoshisato Shibata
Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
Medicina
landiolol
HFpEF
HFmrEF
HFrEF
β-blocker
title Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
title_full Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
title_fullStr Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
title_full_unstemmed Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
title_short Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
title_sort differential effects of landiolol in patients with atrial fibrillation and atrial tachycardia
topic landiolol
HFpEF
HFmrEF
HFrEF
β-blocker
url https://www.mdpi.com/1648-9144/60/11/1782
work_keys_str_mv AT kengoayabe differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT tomoyoshikomiyama differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT hiroyukitakekawa differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT honsakang differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT yasuakitsumagari differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT miwaito differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT keiichiashikaga differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia
AT yoshisatoshibata differentialeffectsoflandiololinpatientswithatrialfibrillationandatrialtachycardia